Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. November 2023 13:20 ET | Quelle: The Rosen Law Firm PA

ROSEN, THE FIRST FILING FIRM, Encourages Paycom Software, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm – PAYC

NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
16. November 2023 13:55 ET | Quelle: The Rosen Law Firm PA

NATIONALLY RANKED ROSEN LAW FIRM Encourages Paycom Software, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – PAYC

NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
21. September 2021 08:00 ET | Quelle: Zenith Capital Corp.

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study

CALGARY, Alberta, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) and Newsoara BioPharma Co., Ltd. (“Newsoara”) announced today the initiation of a...
27. Juni 2019 08:30 ET | Quelle: Zenith Capital Corp.

Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
18. März 2019 09:00 ET | Quelle: Zenith Capital Corp.

Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program

Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019 Phase 2 mCRPC program and clinical data to be presented at AACR CALGARY, Alberta, March 18, 2019 (GLOBE...
20. November 2018 08:30 ET | Quelle: Zenith Capital Corp.

Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer

Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019 CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith...